Insilico Medicine Rides ISM8969 Deals And AI Platform To Strong Rally

Simply Wall St.02-02

Insilico Medicine Cayman TopCo (SEHK:3696) is pushing its ISM8969 NLRP3 inhibitor program forward through new co development deals, regulatory clearance and product progress. The company has signed ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608841598?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683","is_english":true,"pubTime":"2026-02-02 05:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608841598","market":"sg","top_or_hot":-1,"title":"Insilico Medicine Rides ISM8969 Deals And AI Platform To Strong Rally","media":"Simply Wall St.","content":"<div>\n<p>Insilico Medicine Cayman TopCo (SEHK:3696) is pushing its ISM8969 NLRP3 inhibitor program forward through new co development deals, regulatory clearance and product progress. The company has signed ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3696/insilico-medicine-cayman-topco-shares/news/insilico-medicine-rides-ism8969-deals-and-ai-platform-to-str\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine Rides ISM8969 Deals And AI Platform To Strong Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine Rides ISM8969 Deals And AI Platform To Strong Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-02 05:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3696/insilico-medicine-cayman-topco-shares/news/insilico-medicine-rides-ism8969-deals-and-ai-platform-to-str><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Insilico Medicine Cayman TopCo (SEHK:3696) is pushing its ISM8969 NLRP3 inhibitor program forward through new co development deals, regulatory clearance and product progress. The company has signed ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3696/insilico-medicine-cayman-topco-shares/news/insilico-medicine-rides-ism8969-deals-and-ai-platform-to-str\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3696/insilico-medicine-cayman-topco-shares/news/insilico-medicine-rides-ism8969-deals-and-ai-platform-to-str","article_id":"2608841598","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551730-choice2-main-header/1585186975683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3696/insilico-medicine-cayman-topco-shares/news/insilico-medicine-rides-ism8969-deals-and-ai-platform-to-str","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608841598","pubTimestamp":1769980860,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Insilico Medicine Cayman TopCo (SEHK:3696) is pushing its ISM8969 NLRP3 inhibitor program forward through new co development deals, regulatory clearance and product progress.\nThe company has signed collaborations with Qilu Pharmaceutical and Hygtia Therapeutics around ISM8969 for central nervous system and inflammatory diseases, with global rights and large contract values attached.\nISM8969 has received US FDA clearance for a Phase I trial in healthy volunteers, targeting conditions that...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","BK4543":"AI","BK4551":"寇图资本持仓","BK1141":"生命科学工具和服务","03696":"英矽智能","BK4587":"ChatGPT概念","BK4528":"SaaS概念","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Insilico Medicine借助ISM8969交易和人工智能平台强劲反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":0.9},"content_text":"Insilico Medicine Cayman TopCo (SEHK:3696) is pushing its ISM8969 NLRP3 inhibitor program forward through new co development deals, regulatory clearance and product progress. The company has signed collaborations with Qilu Pharmaceutical and Hygtia Therapeutics around ISM8969 for central nervous system and inflammatory diseases, with global rights and large contract values attached. ISM8969 has received US FDA clearance for a Phase I trial in healthy volunteers, targeting conditions that include neurodegenerative diseases such as Parkinson's. Insilico has also introduced Science MMAI Gym, an AI drug development training and discovery platform aimed at industry partners.  For investors watching SEHK:3696, these updates land at a time when the stock is trading at HK$62.9, with a 69.4% return over the past 30 days and 67.4% return year to date. That kind of recent move suggests the market is paying close attention to pipeline progress and new business models around Insilico's AI technology. Looking ahead, the key questions for you are how the ISM8969 trials progress, how quickly the Qilu and Hygtia partnerships translate into clinical and commercial milestones, and how widely Science MMAI Gym is adopted by external pharma and biotech users. These factors will help shape how durable Insilico's current momentum in AI driven drug discovery and external collaborations may be. Stay updated on the most important news stories for InSilico Medicine Cayman TopCo by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on InSilico Medicine Cayman TopCo. SEHK:3696 Earnings & Revenue Growth as at Feb 2026 How InSilico Medicine Cayman TopCo stacks up against its biggest competitors AdvertisementQuick Assessment  ⚖️ Price vs Analyst Target: With no analyst price target available, you are flying without a consensus reference point here. ⚖️ Simply Wall St Valuation: Simply Wall St does not have a clear DCF based value for SEHK:3696, so the valuation status is currently unknown. ✅ Recent Momentum: A 69.4% return over 30 days signals very strong recent momentum as the ISM8969 and MMAI Gym updates hit the market.  Check out Simply Wall St's\nin depth valuation analysis for InSilico Medicine Cayman TopCo. Key Considerations  📊 The ISM8969 partnerships, FDA clearance and MMAI Gym platform all speak to how much of the story rests on pipeline execution and monetising AI capabilities. 📊 Keep an eye on Phase I data for ISM8969, any disclosed milestone payments from Qilu and Hygtia, MMAI Gym adoption by paying partners, and how those feed into revenue against the current loss making profile and a P/E of 103.5x. ⚠️ Major red flags include negative shareholders equity, illiquid trading and a 21.7% revenue decline over the past year, which can all magnify the impact if sentiment turns.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete InSilico Medicine Cayman TopCo analysis.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608841598","isCrawlerRequest":true}